Fludarabine (Fludara)

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, University of Illinois at Chicago, He Huang

Conditions

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, Relapsed, AdultChronic Myeloid Leukemia - Accelerated PhaseHematologic DiseaseHematologic DiseasesLeukemiaMyelodysplastic Syndromes

Phase 1

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingNCT06809699

He HuangHematologic Diseases

Start: 2022-08-04End: 2027-10-31Target: 29Updated: 2025-02-05

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingNCT06809712

He HuangHematologic Disease

Start: 2022-08-04End: 2027-10-31Target: 29Updated: 2025-02-05

Phase 2

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

TerminatedNCT00499889

M.D. Anderson Cancer CenterLeukemia

Start: 2003-02-28End: 2009-11-30Updated: 2012-04-23

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

RecruitingNCT06802315

University of Illinois at ChicagoAcute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult, Chronic Myeloid Leukemia - Accelerated Phase +1

Start: 2025-02-04End: 2032-03-31Target: 38Updated: 2025-06-25